{"entity":{"id":"seekincare","kind":"drug","name":"SeekInCare","aka":[],"tldr":"SeekIn's multi-omic blood test that adds DNA sequencing to its protein test; in published studies it found about six to seven in ten cancers and about four in ten at stage I.","summary":"In Li et al. (Journal of Molecular Diagnostics 2025), a retrospective set of 617 patients with 27 cancer types and 580 without cancer gave 60.0% sensitivity at 98.3% specificity, with 37.7%, 50.4%, 66.7% and 78.1% at stages I to IV; in a prospective cohort of 1,203 people who received it as a laboratory-developed test (median follow-up 753 days) it gave 70.0% sensitivity at 95.2% specificity. SeekIn describes it as CE-marked. A modelling paper estimated a cost of $143 per person screened; that is modelled, not a list price, and no price was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"SeekIn: SeekInCare","url":"https://www.seekincancer.com/seekincare"},{"label":"Li et al., Journal of Molecular Diagnostics 2025","url":"https://doi.org/10.1016/j.jmoldx.2025.04.001"}],"tags":["test","mced","evidence:insufficient"],"related":["oncoseek"],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","fragmentomics","proteomics"],"targets":[],"drugs":[],"companies":["seekin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-seekincare-j-mol-diagn-2025"],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"SeekInCare","modality":"Multi-cancer early detection blood test (shallow whole-genome cell-free DNA plus seven proteins)","mechanism":"Shallow whole-genome sequencing of cell-free DNA for copy number, fragment size, end motifs and viral DNA, combined with seven protein tumour markers by artificial intelligence, with a predicted organ.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/seekincare/","neighbours":{"drug":[{"id":"oncoseek","kind":"drug","name":"OncoSeek","route":"/drugs/oncoseek/"}],"technology":[{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"company":[{"id":"seekin","kind":"company","name":"SeekIn","route":"/companies/seekin/"}],"paper":[{"id":"paper-seekincare-j-mol-diagn-2025","kind":"paper","name":"Clinical Validation of a Noninvasive Multi-Omics Method for Multicancer Early Detection in Retrospective and Prospective Cohorts","route":"/key-papers/paper-seekincare-j-mol-diagn-2025/"}]}}